Placebo for olaparib

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, AstraZeneca

Conditions

Carcinoma, Non-Small-Cell LungFallopian Tube CancerLung NeoplasmsNon-small Cell Lung Cancer NSCLCOvarian CancerPeritoneal Neoplasms

Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruitingNCT03775486

AstraZenecaNon-small Cell Lung Cancer NSCLC

Start: 2018-12-21End: 2026-09-27Updated: 2026-02-10

Phase 3

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Active, not recruitingNCT03740165

Merck Sharp & Dohme LLCFallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms

Start: 2018-12-18End: 2026-05-29Updated: 2025-10-22

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Active, not recruitingNCT04380636

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung, Lung Neoplasms

Start: 2020-07-06End: 2027-02-15Target: 870Updated: 2025-08-17

Related Papers

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

2025-10-01

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

British Journal of Cancer2024-07-0617 citations

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Nature Communications2023-09-0621 citations

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Journal of Clinical Oncology2023-08-2989 citations

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.

2023-06-298 citations

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.

2022-08-1136 citations

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

OncoImmunology2022-06-1846 citations

Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.

2022-04-2917 citations

KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer.

2021-11-01

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

Journal of Clinical Oncology2021-05-202 citations

ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

Journal of Clinical Oncology2019-05-2028 citations

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-05-204 citations